
PMC:7784786 / 1026-1930
Annnotations
LitCovid-PubTator
Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
---|---|---|---|---|---|
60 | 12-20 | Species | denotes | patients | Tax:9606 |
61 | 155-165 | Species | denotes | SARS-COV-2 | Tax:2697049 |
62 | 508-516 | Species | denotes | patients | Tax:9606 |
63 | 640-648 | Species | denotes | patients | Tax:9606 |
64 | 667-675 | Species | denotes | patients | Tax:9606 |
65 | 167-177 | Chemical | denotes | Itolizumab | MESH:C000597346 |
66 | 530-540 | Chemical | denotes | itolizumab | MESH:C000597346 |
67 | 590-600 | Chemical | denotes | Itolizumab | MESH:C000597346 |
68 | 3-11 | Disease | denotes | COVID-19 | MESH:C000657245 |
69 | 22-34 | Disease | denotes | inflammation | MESH:D007249 |
70 | 91-103 | Disease | denotes | inflammation | MESH:D007249 |
71 | 335-344 | Disease | denotes | psoriasis | MESH:D011565 |
72 | 393-405 | Disease | denotes | inflammation | MESH:D007249 |
73 | 484-498 | Disease | denotes | critically ill | MESH:D016638 |
74 | 499-507 | Disease | denotes | COVID-19 | MESH:C000657245 |
75 | 620-632 | Disease | denotes | inflammation | MESH:D007249 |
76 | 860-868 | Disease | denotes | COVID-19 | MESH:C000657245 |
77 | 894-903 | Disease | denotes | mortality | MESH:D003643 |
LitCovid-PD-HP
Id | Subject | Object | Predicate | Lexical cue | hp_id |
---|---|---|---|---|---|
T4 | 335-344 | Phenotype | denotes | psoriasis | http://purl.obolibrary.org/obo/HP_0003765 |
LitCovid-sentences
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T12 | 0-85 | Sentence | denotes | In COVID-19 patients, inflammation is associated with the progression of the disease. |
T13 | 86-166 | Sentence | denotes | This inflammation comes from immune system activation in response to SARS-COV-2. |
T14 | 167-245 | Sentence | denotes | Itolizumab is an antibody that recognizes a protein expressed in immune cells. |
T15 | 246-345 | Sentence | denotes | The antibody has shown to be safe and efficacious in the treatment of moderate to severe psoriasis. |
T16 | 346-435 | Sentence | denotes | Its effect is associated with the reduction of inflammation and immune system activation. |
T17 | 436-589 | Sentence | denotes | Here, we report the outcome of three severe and critically ill COVID-19 patients treated with itolizumab as part of an expanded access clinical protocol. |
T18 | 590-649 | Sentence | denotes | Itolizumab was able to reduce inflammation in all patients. |
T19 | 650-749 | Sentence | denotes | Two of the three patients showed respiratory and radiological improvement and were fully recovered. |
T20 | 750-904 | Sentence | denotes | We hypothesize this anti-inflammatory therapy in addition to antiviral and anticoagulant therapy could reduce COVID-19 associated morbidity and mortality. |